t
| Date | 21 Jun 2022 |
| Time | 07:00:06 |
| Category | Director/PDMR dealings |
| ID | 5538P |
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Director/PDMR Shareholding
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that it has been notified that on 20 June 2022 Julian Baines, Non-Executive Deputy Chairman, purchased a total of 11,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 32.596 pence per Ordinary Share.
Following this transaction, Julian Baines' total direct and indirect interest in the Group is 1,616,288 Ordinary Shares representing approximately 0.36% of the Group's total issued share capital.
The Notification of Dealing Form required in accordance with UK MAR is set out below.
|
EKF Diagnostics Holdings plc |
|||
|
Mike Salter, CEO |
Tel: +44 (0)29 2071 0570 |
||
|
Marc Davies, CFO |
|
||
|
|
|
||
|
Singer Capital Markets (Nominated Adviser & Joint Broker) |
Tel: +44 (0)20 7496 3000 |
||
|
Aubrey Powell / George Tzimas |
|
||
|
|
|
||
|
Investec Bank plc (Joint Broker) |
Tel: +44 (0)20 7597 4000 |
||
|
Gary Clarence / Daniel Adams / Ben Farrow |
|
||
|
|
|
||
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or [email protected] |
||
|
Paul McManus / Lianne Applegarth |
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 |
||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Julian Baines
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Non-Executive Deputy Chairman |
|||
|
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
EKF Diagnostics Holdings plc |
|||
|
b)
|
LEI
|
213800DXTF3EAUK1AR05 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of £0.01 each |
|||
|
|
|
||||
|
Identification code |
GB0031509804 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
32.596 pence |
11,000 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
N/A - Single Transaction |
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
20 June 2022 |
|||
|
f)
|
Place of the transaction
|
London Stock Exchange - AIMX |
|||
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:
|
Point-of-Care |
Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.
|
|
Central Laboratory |
Clinical chemistry, Small lab analysers, Centrifuges Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycates Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin
|
|
Life Sciences |
Enzyme fermentation, Custom products and Bulk fermentation
|
|
Contract Manufacturing |
Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits
|
|
Laboratory Services |
In September 2021, EKF completed the acquisition of Advanced Diagnostic Laboratory LLC ("ADL Health"), a Texas based testing laboratory certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing. The laboratory provides testing for a variety of clinical, forensic and microbiological sample types using a range of analytical techniques. This acquisition positions EKF as a leading 'one stop' provider of diagnostic products and services from sample collection to results. |
EKF's growth strategy to 2024 and beyond can be summarised as:
|
• |
continuing innovation in products and services in Point-of-Care, Central Laboratory and Life Sciences leveraging new and existing routes to market and relationships; |
|
• |
investment in expanded production and kitting capabilities to offer a suite of diagnostic Contract Manufacturing solutions to third party businesses; |
|
• |
expansion of CLIA Laboratories Testing offering, building on the acquired capabilities in ADL Health; and |
|
• |
concluding complementary earnings-enhancing acquisitions with key strategic value. |
EKF will also continue to generate enhanced shareholder value through:
|
• |
a progressive dividend policy; and |
|
• |
its agreement with Mount Sinai Innovation Partners ("MSIP"), which allows us advanced access to innovative commercial opportunities and where we can build on the ongoing successes of Renalytix plc, Verici Dx plc and Trellus Health plc. |